Skandinaviska Enskilda Banken AB publ Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Skandinaviska Enskilda Banken AB publ increased its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 52.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 289,273 shares of the company's stock after buying an additional 99,801 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.13% of Sana Biotechnology worth $483,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in Sana Biotechnology by 604.8% in the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after purchasing an additional 625,481 shares during the period. Two Sigma Advisers LP lifted its position in Sana Biotechnology by 677.0% in the fourth quarter. Two Sigma Advisers LP now owns 209,000 shares of the company's stock valued at $341,000 after purchasing an additional 182,100 shares during the period. Two Sigma Investments LP lifted its position in Sana Biotechnology by 228.4% in the fourth quarter. Two Sigma Investments LP now owns 480,298 shares of the company's stock valued at $783,000 after purchasing an additional 334,042 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Sana Biotechnology by 10.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company's stock valued at $455,000 after purchasing an additional 25,383 shares during the period. Finally, Geode Capital Management LLC lifted its position in Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after purchasing an additional 26,601 shares during the period. Institutional investors and hedge funds own 88.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on SANA. JMP Securities restated a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $9.17.

Sana Biotechnology Stock Down 3.7%

Shares of SANA traded down $0.15 during mid-day trading on Friday, reaching $3.91. 4,047,337 shares of the company's stock were exchanged, compared to its average volume of 5,424,191. The company has a 50-day simple moving average of $3.33 and a two-hundred day simple moving average of $2.68. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.30. The company has a market cap of $881.63 million, a price-to-earnings ratio of -4.44 and a beta of 1.90.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. As a group, equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.